--- title: "Adjuvant Ovarian Cancer NRG-GY036 | Sutter Health" description: "A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy" url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Adjuvant Ovarian Cancer NRG-GY036 # Adjuvant Ovarian Cancer NRG-GY036 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06580314). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib. ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Ovarian%20Cancer%20NRG-GY036%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB](https://www.sutterhealth.org/research/clinical-trials/adjuvant-advance-ovarian-cancer-framework-01-j5e-mc-jzxb-2066913418) FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. **Status:** Open to Enrollment - Clinical trial ### [Advanced Ovarian Cancer Catalina-2](https://www.sutterhealth.org/research/clinical-trials/advanced-ovarian-cancer-catalina-2-2023017569) Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002) **Status:** Open to Enrollment - Clinical trial ### [Advanced Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer GOG-3115](https://www.sutterhealth.org/research/clinical-trials/advanced-serous-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer-gog-3115-2041490051) A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRĪ±-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer **Status:** Open to Enrollment - Clinical trial ### [Neoadjuvant Ovarian Cancer DESTINY-Ovarian01](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-ovarian-cancer-destiny-ovarian01-2060813496) A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13) **Status:** Open to Enrollment - Clinical trial ### [Ovarian Cancer M25-709 FLORENZA](https://www.sutterhealth.org/research/clinical-trials/ovarian-cancer-m25-709-florenza-2040407243) A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Ovarian Cancer NRG-GY036"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362#medicalwebpage","name":"Adjuvant Ovarian Cancer NRG-GY036","description":"A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362","inLanguage":"en-US","dateModified":"2026-08-11","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362#breadcrumblist"}} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362#medicaltrial","name":"Adjuvant Ovarian Cancer NRG-GY036","alternateName":"A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-ovarian-cancer-nrg-gy036-2015844362","description":"This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.","identifier":"NCT06580314","code":{"@type":"MedicalCode","codeValue":"NCT06580314","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06580314","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Ovarian Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```